Prostate cancer — all decisions

The Veteran was granted special monthly compensation (SMC) based on the need for aid and attendance due to his service-connected atherosclerotic cardiovascular disease and prostate cancer, as well as SMC pursuant to 38 U.S.C. § 1114(o) and a higher level of care under 38 U.S.C. § 1114(r)(2).

The appeal of the proposed action to sever service connection for a chronic left foot disability, to include corns and calluses, was dismissed. The Board also denied service connection for an allergen disability and remanded several other claims for further development.

The appeal was granted for readjudicating the back condition claim, but denied for diabetes mellitus and prostate cancer. The claims for diabetes and prostate cancer were remanded.

The Board denied the Veteran's claims for service connection for prostate cancer and coronary artery disease, finding no evidence of in-service exposure to herbicides or other relevant factors.

The Board remands the issues of service connection for various disabilities and the character of discharge issue, as additional evidence and clarification are needed.

The appeal to readjudicate the claims of service connection for prostate cancer and throat cancer was denied as new and relevant evidence has not been received.

The Veteran's service-connected disabilities, specifically his prostate cancer, result in the loss of use of both lower extremities such as to preclude locomotion without the aid of a wheelchair. Therefore, he is granted entitlement to specially adapted housing.

The Board remands the claim for service connection of prostate cancer due to TERA to satisfy a pre-decisional duty to assist error.

The Board remands the claims for service connection for diabetes mellitus, prostate cancer, mucinous adenocarcinoma, heart condition, and bilateral lower extremity peripheral neuropathy to allow verification of herbicide agent exposure in Okinawa, Japan, and to obtain new VA examinations.

The Board denied the appellant's eligibility for direct payment of attorney fees from past due benefits awarded in a November 2023 rating decision granting service connection for prostate cancer residuals.

The Board denied service connection for a prostate disorder, including prostate cancer and benign prostatic hypertrophy, and dismissed the appeals for diabetes mellitus, hypertension, bilateral upper and lower extremity peripheral neuropathy, and sleep apnea due to untimeliness of the appeal.

The Board remands the Veteran's claims for service connection for hypertension and prostate cancer due to insufficient evidence regarding potential herbicide exposure during his active service.

The Board denied the Veteran's claim for service connection for prostate cancer, finding no evidence that it was related to his military service.

The Board denied service connection for diabetes mellitus, type II, cardiovascular disability, hypertension, thyromegaly, prostate cancer, and bladder cancer as there is no evidence of in-service exposure to herbicide agents or that the disabilities are related to such exposure.

The Board granted service connection for prostate cancer and erectile dysfunction, both on a direct basis with the presumption of exposure to herbicides due to the Veteran's service at Korat RTAFB.

The Board remands the claim for service connection of prostate cancer and residuals, to include urinary frequency, due to a lack of medical evidence linking these conditions to the Veteran's military service.

The Board remands the claim for service connection of prostate cancer to obtain a new medical opinion, as the previous examination was found inadequate.

The Board denied an earlier effective date for the grant of service connection for prostate cancer, finding that July 11, 2016, is the proper effective date.

The Veteran was granted an effective date of December 12, 2023, for the 60 percent evaluation of prostate cancer status post robotic assisted radical retropubic with residual voiding dysfunction. The claims for earlier effective dates for a painful prostatectomy scar and sleep apnea with pleural plaques were denied.

The Board granted service connection for prostate cancer, to include as due to herbicide exposure, based on new and relevant evidence.